TGFB1 and neoplasm: Although the major mechanisms of resistance to cancer immunotherapy have not been fully established, the inhibition of TGF-β signaling and modifying the tumor microenvironment may overcome tumor resistance to PD1\PD-L1 blockers [127,128].